Alterity Therapeutics (ATHE) shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.
The result was achieved at the 50 mg dose at week 52 when compared with placebo, Alterity said.
The company also said that ATH434 was well-tolerated, with no reported serious adverse events.
Price: 5.48, Change: +2.49, Percent Change: +83.28
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。